FRET based ratio-metric sensing of hyaluronidase in synthetic urine as a biomarker for bladder and prostate cancer

Rahul Chib, Sangram Raut, Rafal Fudala, Aaron Chang, Mark Mummert, Ryan Rich, Zygmunt Gryczynski, Ignacy Gryczynski

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Elevated hyaluronidase levels are found in the urine of bladder and prostate cancer patients. Therefore, HA-ase is regarded as an important biomarker for the detection of these cancers. In this report, we use a FRET based ratiometric sensing approach to detect the level of HA-ase in synthetic urine. For this, we have used a HA-FRET probe (hyaluronan) labeled with fluorescein as a donor and rhodamine as an acceptor. We monitor the digestion of our HA-FRET probe with different concentrations of HA-ase in synthetic urine via fluorescence emission. The extent to which FRET is released depends on the concentration of HA-ase. Our fluorescence intensity results are also supported with time resolved fluorescence decay data. This assay can be used to develop a non-invasive technique for the detection of bladder and/or prostate cancer progression.

Original languageEnglish
Pages (from-to)470-474
Number of pages5
JournalCurrent Pharmaceutical Biotechnology
Volume14
Issue number4
DOIs
StatePublished - 2013

Keywords

  • Bladder cancer
  • HA-FRET
  • Hyaluronidase
  • Ratiometric sensing

Fingerprint

Dive into the research topics of 'FRET based ratio-metric sensing of hyaluronidase in synthetic urine as a biomarker for bladder and prostate cancer'. Together they form a unique fingerprint.

Cite this